{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:30:38Z","timestamp":1792791038294,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Multidisciplinary Cooperative Diagnosis and Treatment Capacity","award":["lung cancer z027002"],"award-info":[{"award-number":["lung cancer z027002"]}]},{"name":"Clinical Research Special Fund of Wu Jieping Medical Foundation","award":["320.6750.2023-5-109"],"award-info":[{"award-number":["320.6750.2023-5-109"]}],"id":[{"id":"https:\/\/ror.org\/05dgwj702","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Clinical Research Center for Geriatric Disorders","award":["No. 2022LNJJ10"],"award-info":[{"award-number":["No. 2022LNJJ10"]}],"id":[{"id":"https:\/\/ror.org\/03ddkvp86","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Research Project of Hunan Provincial Health Commission","award":["W20242005"],"award-info":[{"award-number":["W20242005"]}]},{"name":"Advanced Lung Cancer Targeted Therapy Research Foundation of China","award":["CTONG-YC20210303"],"award-info":[{"award-number":["CTONG-YC20210303"]}]},{"name":"Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province","award":["CXPJJH121005-01"],"award-info":[{"award-number":["CXPJJH121005-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91863-7","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:40:21Z","timestamp":1740728421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Ruoyu","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"91863_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol, A. S. et al. Brain metastases. Nat. Rev. Dis. Primers 5, 5. https:\/\/doi.org\/10.1038\/s41572-018-0055-y (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"91863_CR2","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney, D. N. et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study. Neuro. Oncol. 19, 1511\u20131521. https:\/\/doi.org\/10.1093\/neuonc\/nox077 (2017).","journal-title":"Neuro. Oncol."},{"key":"91863_CR3","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","volume":"19","author":"SN Waqar","year":"2018","unstructured":"Waqar, S. N. et al. Non-small-cell lung cancer with brain metastasis at presentation. Clin. Lung Cancer 19, e373\u2013e379. https:\/\/doi.org\/10.1016\/j.cllc.2018.01.007 (2018).","journal-title":"Clin. Lung Cancer"},{"key":"91863_CR4","doi-asserted-by":"publisher","first-page":"103119","DOI":"10.1016\/j.critrevonc.2020.103119","volume":"156","author":"G Lamberti","year":"2020","unstructured":"Lamberti, G. et al. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Crit. Rev. Oncol. Hematol. 156, 103119. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103119 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"91863_CR5","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1200\/edbk_100006","volume":"35","author":"VA Venur","year":"2016","unstructured":"Venur, V. A. & Ahluwalia, M. S. Targeted therapy in brain metastases: Ready for primetime?. Am. Soc. Clin. Oncol. Educ. Book 35, e123-130. https:\/\/doi.org\/10.1200\/edbk_100006 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"91863_CR6","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard, D. et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv192\u2013iv237. https:\/\/doi.org\/10.1093\/annonc\/mdy275 (2018).","journal-title":"Ann. Oncol."},{"key":"91863_CR7","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/jco.22.00825","volume":"40","author":"N Singh","year":"2022","unstructured":"Singh, N. et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline. J. Clin. Oncol. 40, 3323\u20133343. https:\/\/doi.org\/10.1200\/jco.22.00825 (2022).","journal-title":"J. Clin. Oncol."},{"key":"91863_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/CAD.0000000000001118","volume":"32","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A., Dall\u2019Olio, F. G., Altimari, A., Giunchi, F. & Ardizzoni, A. Role of PD-L1 assessment in advanced NSCLC: Does it still matter?. Anticancer Drugs 32, 1084\u20131085. https:\/\/doi.org\/10.1097\/CAD.0000000000001118 (2021).","journal-title":"Anticancer Drugs"},{"key":"91863_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101835","author":"TK Sahin","year":"2024","unstructured":"Sahin, T. K., Rizzo, A., Aksoy, S. & Guven, D. C. Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: A systematic review and meta-analysis. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers16101835 (2024).","journal-title":"Cancers (Basel)"},{"key":"91863_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41416-022-01929-w","volume":"127","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A. Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: A matter of debate. Br. J. Cancer 127, 1381\u20131382. https:\/\/doi.org\/10.1038\/s41416-022-01929-w (2022).","journal-title":"Br. J. Cancer"},{"key":"91863_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven, D. C. et al. Immune checkpoint inhibitor-related hearing loss: A systematic review and analysis of individual patient data. Support Care Cancer 31, 624. https:\/\/doi.org\/10.1007\/s00520-023-08083-w (2023).","journal-title":"Support Care Cancer"},{"key":"91863_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A. et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: The MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol. 17, 1455\u20131466. https:\/\/doi.org\/10.1080\/17425255.2021.2029405 (2021).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"91863_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2022.09.031","volume":"177","author":"G Viscardi","year":"2022","unstructured":"Viscardi, G. et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: A systematic review and meta-analysis. Eur. J. Cancer 177, 175\u2013185. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.031 (2022).","journal-title":"Eur. J. Cancer"},{"key":"91863_CR14","doi-asserted-by":"crossref","unstructured":"Nadal, E. et al. Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer with untreated brain metastases. Journal of Clinical Oncology 40 (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.9010"},{"key":"91863_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","volume":"128","author":"SM Gadgeel","year":"2019","unstructured":"Gadgeel, S. M. et al. Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer 128, 105\u2013112. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.017 (2019).","journal-title":"Lung Cancer"},{"key":"91863_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100205","author":"AS Mans","year":"2021","unstructured":"Mans, A. S. et al. Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC With brain metastases: Pooled analysis of KEYNOTE-001, 010, 024, and 042. Jto Clin. Res. Rep. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100205 (2021).","journal-title":"Jto Clin. Res. Rep."},{"key":"91863_CR17","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","volume":"16","author":"SF Powell","year":"2021","unstructured":"Powell, S. F. et al. Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: Pooled analysis of KEYNOTE-021,-189, and-407. J. Thorac. Oncol. 16, 1883\u20131892. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.020 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"91863_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/s1470-2045(20)30111-x","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial. Lancet Oncol. 21, 655\u2013663. https:\/\/doi.org\/10.1016\/s1470-2045(20)30111-x (2020).","journal-title":"Lancet Oncol."},{"key":"91863_CR19","doi-asserted-by":"publisher","first-page":"S1430","DOI":"10.1016\/j.annonc.2021.10.141","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Nivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1. Ann. Oncol. 32, S1430\u2013S1431. https:\/\/doi.org\/10.1016\/j.annonc.2021.10.141 (2021).","journal-title":"Ann. Oncol."},{"key":"91863_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722\u2013730. https:\/\/doi.org\/10.1056\/NEJMoa1805453 (2018).","journal-title":"N. Engl. J. Med."},{"key":"91863_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/s1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long, G. V. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study. Lancet Oncol. 19, 672\u2013681. https:\/\/doi.org\/10.1016\/s1470-2045(18)30139-6 (2018).","journal-title":"Lancet Oncol."},{"key":"91863_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061404","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A. et al. Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: A systematic review and meta-analysis. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14061404 (2022).","journal-title":"Cancers (Basel)"},{"key":"91863_CR23","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1158\/0008-5472.Can-04-1525","volume":"64","author":"CT Garnett","year":"2004","unstructured":"Garnett, C. T. et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64, 7985\u20137994. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-1525 (2004).","journal-title":"Cancer Res."},{"key":"91863_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032542","author":"S Wan","year":"2012","unstructured":"Wan, S. et al. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. Plos One https:\/\/doi.org\/10.1371\/journal.pone.0032542 (2012).","journal-title":"Plos One"},{"key":"91863_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12967-023-04089-4","volume":"21","author":"W Tian","year":"2023","unstructured":"Tian, W., Chu, X., Tanzhu, G. & Zhou, R. Optimal timing and sequence of combining stereotactic radiosurgery with immune checkpoint inhibitors in treating brain metastases: Clinical evidence and mechanistic basis. J. Transl. Med. 21, 244. https:\/\/doi.org\/10.1186\/s12967-023-04089-4 (2023).","journal-title":"J. Transl. Med."},{"key":"91863_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00193","author":"H Menon","year":"2019","unstructured":"Menon, H. et al. Role of radiation therapy in modulation of the tumor stroma and microenvironment. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.00193 (2019).","journal-title":"Front. Immunol."},{"key":"91863_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313\u2013322. https:\/\/doi.org\/10.1038\/nrc.2018.6 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"91863_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728\u2013734 (2005).","journal-title":"Clin. Cancer Res."},{"key":"91863_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092572","author":"Y Yoshimoto","year":"2014","unstructured":"Yoshimoto, Y. et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. Plos One https:\/\/doi.org\/10.1371\/journal.pone.0092572 (2014).","journal-title":"Plos One"},{"key":"91863_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess, A. P. et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment. Int. J. Radiat. Oncol. Biol. Phys. 92, 368\u2013375. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.004 (2015).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"91863_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep19740","author":"CT Wu","year":"2016","unstructured":"Wu, C. T., Chen, W. C., Chang, Y. H., Lin, W. Y. & Chen, M. F. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci. Rep. https:\/\/doi.org\/10.1038\/srep19740 (2016).","journal-title":"Sci. Rep."},{"key":"91863_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMc1900407","volume":"380","author":"YH Kim","year":"2019","unstructured":"Kim, Y. H. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 380, 989\u2013990 (2019).","journal-title":"N. Engl. J. Med."},{"key":"91863_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11060-023-04459-4","volume":"165","author":"Y Yu","year":"2023","unstructured":"Yu, Y. et al. Improved survival outcome with not-delayed radiotherapy and immediate PD-1\/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases. J. Neurooncol. 165, 127\u2013137. https:\/\/doi.org\/10.1007\/s11060-023-04459-4 (2023).","journal-title":"J. Neurooncol."},{"key":"91863_CR34","doi-asserted-by":"publisher","first-page":"100655","DOI":"10.1016\/j.jtocrr.2024.100655","volume":"5","author":"T Tozuka","year":"2024","unstructured":"Tozuka, T. et al. Immunotherapy with radiotherapy for brain metastases in patients with NSCLC: NEJ060. JTO Clin. Res. Rep. 5, 100655. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100655 (2024).","journal-title":"JTO Clin. Res. Rep."},{"key":"91863_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213689","author":"TK Sahin","year":"2024","unstructured":"Sahin, T. K., Ayasun, R., Rizzo, A. & Guven, D. C. Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: A systematic review and meta-analysis. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers16213689 (2024).","journal-title":"Cancers (Basel)"},{"key":"91863_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3340\/jkns.2020.0135","volume":"64","author":"MH Lee","year":"2021","unstructured":"Lee, M. H. et al. Immune checkpoint inhibitors for non-small-cell lung cancer with brain metastasis\u202f: The role of gamma knife radiosurgery. J. Korean Neurosurg. Soc. 64, 271\u2013281. https:\/\/doi.org\/10.3340\/jkns.2020.0135 (2021).","journal-title":"J. Korean Neurosurg. Soc."},{"key":"91863_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006871","author":"M Altan","year":"2023","unstructured":"Altan, M. et al. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I\/II trial. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2023-006871 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"91863_CR38","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-1061","author":"S Lu","year":"2024","unstructured":"Lu, S. et al. Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: A retrospective study. Future Oncol. https:\/\/doi.org\/10.2217\/fon-2023-1061 (2024).","journal-title":"Future Oncol."},{"key":"91863_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e20601","author":"H Watanabe","year":"2017","unstructured":"Watanabe, H. et al. The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.e20601 (2017).","journal-title":"J. Clin. Oncol."},{"key":"91863_CR40","doi-asserted-by":"publisher","first-page":"875488","DOI":"10.3389\/fimmu.2022.875488","volume":"13","author":"X Chu","year":"2022","unstructured":"Chu, X. et al. The long-term and short-term efficacy of immunotherapy in non-small cell lung cancer patients with brain metastases: A systematic review and meta-analysis. Front. Immunol. 13, 875488. https:\/\/doi.org\/10.3389\/fimmu.2022.875488 (2022).","journal-title":"Front. Immunol."},{"key":"91863_CR41","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jtho.2021.04.014","volume":"16","author":"V Teixeira Loiola de Alencar","year":"2021","unstructured":"Teixeira Loiola de Alencar, V., Guedes Camandaroba, M. P., Pirolli, R., Fogassa, C. A. Z. & Cordeiro de Lima, V. C. Immunotherapy as single treatment for patients with NSCLC with brain metastases: A systematic review and meta-analysis-the META-L-BRAIN study. J. Thorac. Oncol. 16, 1379\u20131391. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.014 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"91863_CR42","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks, L. E. L. et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J. Thorac. Oncol. 14, 1244\u20131254. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.009 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"91863_CR43","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005 (2018).","journal-title":"N. Engl. J. Med."},{"key":"91863_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial. Lancet Respir. Med. 9, 305\u2013314. https:\/\/doi.org\/10.1016\/S2213-2600(20)30365-9 (2021).","journal-title":"Lancet Respir. Med."},{"key":"91863_CR45","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J. Thorac. Oncol. 15, 1636\u20131646. https:\/\/doi.org\/10.1016\/j.jtho.2020.07.014 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"91863_CR46","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","volume":"16","author":"M Nishio","year":"2021","unstructured":"Nishio, M. et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial. J. Thorac. Oncol. 16, 653\u2013664. https:\/\/doi.org\/10.1016\/j.jtho.2020.11.025 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"91863_CR47","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s10637-021-01069-7","volume":"39","author":"N Matsuo","year":"2021","unstructured":"Matsuo, N. et al. Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy. Invest. New Drugs 39, 1150\u20131158. https:\/\/doi.org\/10.1007\/s10637-021-01069-7 (2021).","journal-title":"Invest. New Drugs"},{"key":"91863_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2020.11.003","volume":"32","author":"P Roth","year":"2021","unstructured":"Roth, P. et al. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann. Oncol. 32, 171\u2013182. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.003 (2021).","journal-title":"Ann. Oncol."},{"key":"91863_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2017.08.006","volume":"125","author":"F Teng","year":"2017","unstructured":"Teng, F., Tsien, C. I., Lawrence, T. S. & Cao, Y. Blood-tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy. Radiother. Oncol. 125, 89\u201393. https:\/\/doi.org\/10.1016\/j.radonc.2017.08.006 (2017).","journal-title":"Radiother. Oncol."},{"key":"91863_CR50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1515\/raon-2017-0018","volume":"51","author":"M Harat","year":"2017","unstructured":"Harat, M., Lebioda, A., Lasota, J. & Makarewicz, R. Evaluation of brain edema formation defined by MRI after LINAC-based stereotactic radiosurgery. Radiol. Oncol. 51, 137\u2013141. https:\/\/doi.org\/10.1515\/raon-2017-0018 (2017).","journal-title":"Radiol. Oncol."},{"key":"91863_CR51","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-018-2880-y","volume":"139","author":"K Diao","year":"2018","unstructured":"Diao, K. et al. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: Clinical outcomes and toxicity. J. Neurooncol. 139, 421\u2013429. https:\/\/doi.org\/10.1007\/s11060-018-2880-y (2018).","journal-title":"J. Neurooncol."},{"key":"91863_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","volume":"125","author":"RJ Colaco","year":"2016","unstructured":"Colaco, R. J., Martin, P., Kluger, H. M., Yu, J. B. & Chiang, V. L. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?. J. Neurosurg. 125, 17\u201323. https:\/\/doi.org\/10.3171\/2015.6.JNS142763 (2016).","journal-title":"J. Neurosurg."},{"key":"91863_CR53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/WCO.0000000000001217","volume":"36","author":"A Botticella","year":"2023","unstructured":"Botticella, A. & Dhermain, F. Combination of radiosurgery and immunotherapy in brain metastases: Balance between efficacy and toxicities. Curr. Opin. Neurol. 36, 587\u2013591. https:\/\/doi.org\/10.1097\/WCO.0000000000001217 (2023).","journal-title":"Curr. Opin. Neurol."},{"key":"91863_CR54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-023-04404-5","volume":"164","author":"PA Jablonska","year":"2023","unstructured":"Jablonska, P. A. et al. Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: The risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis. J. Neurooncol. 164, 199\u2013209. https:\/\/doi.org\/10.1007\/s11060-023-04404-5 (2023).","journal-title":"J. Neurooncol."},{"key":"91863_CR55","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cncr.34087","volume":"128","author":"EJ Lehrer","year":"2022","unstructured":"Lehrer, E. J. et al. Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study. Cancer 128, 1429\u20131438. https:\/\/doi.org\/10.1002\/cncr.34087 (2022).","journal-title":"Cancer"},{"key":"91863_CR56","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum, M. A. et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J. Clin. Oncol. 40, 492\u2013516. https:\/\/doi.org\/10.1200\/JCO.21.02314 (2022).","journal-title":"J. Clin. Oncol."},{"key":"91863_CR57","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064\u20135074. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3271 (2014).","journal-title":"Clin. Cancer Res."},{"key":"91863_CR58","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet. Oncol. 17, e542\u2013e551. https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5 (2016).","journal-title":"Lancet. Oncol."},{"key":"91863_CR59","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s00262-022-03224-2","volume":"71","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. Cancer Immunol. Immunother. 71, 3071\u20133085. https:\/\/doi.org\/10.1007\/s00262-022-03224-2 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"91863_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006243","author":"G Xiao","year":"2023","unstructured":"Xiao, G. et al. Heterogeneity of tumor immune microenvironment of EGFR\/ALK-positive tumors versus EGFR\/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-006243 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"91863_CR61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lungcan.2019.04.009","volume":"132","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. Lung Cancer 132, 36\u201338. https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.009 (2019).","journal-title":"Lung Cancer"},{"key":"91863_CR62","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643 (2015).","journal-title":"N. Engl. J. Med."},{"key":"91863_CR63","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X (2017).","journal-title":"Lancet"},{"key":"91863_CR64","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387, 1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7 (2016).","journal-title":"Lancet"},{"key":"91863_CR65","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg, S. B. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976\u2013983. https:\/\/doi.org\/10.1016\/s1470-2045(16)30053-5 (2016).","journal-title":"Lancet Oncol."},{"key":"91863_CR66","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415\u20132426. https:\/\/doi.org\/10.1056\/NEJMoa1613493 (2017).","journal-title":"N. Engl. J. Med."},{"key":"91863_CR67","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","volume":"3","author":"PW Sperduto","year":"2017","unstructured":"Sperduto, P. W. et al. Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 3, 827\u2013831. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3834 (2017).","journal-title":"JAMA Oncol."},{"key":"91863_CR68","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","volume":"77","author":"PW Sperduto","year":"2010","unstructured":"Sperduto, P. W. et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int. J. Radiat. Oncol. Biol. Phys. 77, 655\u2013661. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.025 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91863-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91863-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91863-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:40:39Z","timestamp":1740728439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91863-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91863"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91863-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the guidelines of the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations. The study protocol was approved by the ethics committee of Xiangya Hospital, Central South University (202406122). In accordance with the Ethical Review Methodology for Biomedical Research Involving Humans (2016 Edition) established by the Chinese authorities, the Ethics Committee of Xiangya Hospital, Central South University granted approval for the waiver of patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"7036"}}